Recombinant Human Anti-CD19 x Anti-CD89 Bispecific Antibody (Fab-IgG) (FABIG-H220)

Recombinant Anti-CD19 x Anti-CD89 Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can retarget macrophages to tumor cells. It is designed for the research of B cell lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD89

Type

Fab-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphomaLeukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD89

Gene ID

2204

UniProt ID

P24071

Alternative Names

FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Anti-CD89 Bispecific Antibody (Fab-IgG) (FABIG-H220). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD19 x Anti-CD89 Bispecific Antibody (Fab-IgG) (CAT#: FABIG-H220)

Specifications

Targets

Customer Reviews and Q&As